Claims for Patent: 5,585,466

Summary for Patent: 5,585,466

Title:	Crystals of serum albumin for use in genetic engineering and rational drug design
Abstract:	Serum albumin crystal forms have been produced which exhibit superior x-ray diffraction quality. The crystals are produced from both recombinant and wild-type human serum albumin, canine, and baboon serum albumin and allow the performance of drug-binding studies as well as genetic engineering studies. The crystals are grown from solutions of polyethylene glycol or ammonium sulphate within prescribed limits during growth times from one to several weeks and include the following space groups: P2.sub.1, C2, P1.
Inventor(s):	Carter; Daniel C. (Decatur, AL)
Assignee:	The United States of America as represented by the Administrator of the (Washington, DC)
Application Number:	08/351,861
Patent Claims:	1. A method of growing crystals of serum albumin comprising the steps of: providing an aqueous solution of serum albumin having a concentration of 10 to 220 milligrams per milliliter; providing an aqueous precipitant solution comprising polyethylene glycol having a concentration of 17-30% (v/v) and a molecular weight of 2000 to 8000 and a corresponding buffer solution; mixing a droplet of said aqueous serum albumin solution with a droplet of said precipitant solution; suspending the resulting mixed droplet over a well of precipitant solution in a sealed container, the vapor pressure of the solution in said well being lower than the vapor pressure in the resulting mixed droplet; and allowing the suspended mixed droplet to stand for a period of time such that a serum albumin crystal in said mixed droplet grows to a predetermined size. 2. The method according to claim 1 wherein the buffer solution comprises a monobasic potassium phosphate solution. 3. The method according to claim 1 wherein the concentration of said aqueous serum albumin solution is approximately 120 milligrams per milliliter. 4. The method according to claim 1 wherein the polyethylene glycol has an average molecular weight of 3350. 5. The method according to claim 1 wherein said polyethylene glycol is combined with said corresponding buffer solution having a pH of 6.8 to 7.8. 6. The method according to claim 5 wherein said serum albumin comprises human serum albumin. 7. The method according to claim 6 further comprising the step of adding a long chain fatty acid to the precipitant solution in molar ratios of 0.1 to 10 per human serum albumin molecule. 8. The method according to claim 5 wherein said serum albumin comprises baboon serum albumin. 9. The method according to claim 8 further comprising the step of adding a long chain fatty acid to the precipitant solution in molar ratios of 0.1 to 10 per baboon serum albumin molecule. 10. The method according to claim 1 wherein the aqueous precipitant solution comprises saturated ammonium sulfate having a concentration of 35-50% (v/v). 11. The method according to claim 10 wherein the corresponding buffer solution has a pH of 7.2 to 8.2. 12. The method according to claim 11 wherein said serum albumin comprises canine serum albumin. 13. The method according to claim 12 further comprising the step of adding long chain fatty acids to the precipitant solution in molar ratios of 0.1 to 2 per canine serum albumin molecule. 14. A serum albumin crystal prepared by the method of claim 1, wherein the serum albumin is selected from the group consisting of human serum albumin, baboon serum albumin and canine serum albumin. 15. A method of growing crystals of serum albumin comprising the steps of: providing an aqueous solution of serum albumin having a concentration of 10 to 120 milligrams per milliliter; providing an aqueous precipitant solution comprising polyethylene glycol having a concentration of 17-30% (v/v) and a molecular weight of 2000 to 8000 and a corresponding buffer; combining said serum albumin solution with said precipitant solution and allowing the combined solution to stand for a predetermined time until a serum albumin crystal therein grows to a predetermined size. 16. The method according to claim 15 wherein said serum albumin solution is disposed within a semipermeable size exclusion membrane and said precipitant solution is combined with the serum albumin solution by diffusion through said membrane. 17. The method according to claim 15 wherein said step of combining precipitant solution comprises slowly adding the serum albumin solution to the precipitant solution, sealing the resulting solution in a container and allowing the resulting solution to stand. 18. The method according to claim 15 wherein said corresponding buffer solution has a pH of 6.5 to 8.0. 19. The method according to claim 18 wherein said serum albumin comprises human serum albumin. 20. The method according to claim 18 wherein said serum albumin comprises baboon serum albumin. 21. The method according to claim 18 wherein the aqueous precipitant solution comprises 50-70% (v/v) saturated ammonium sulfate solution. 22. The method according to claim 21 wherein said corresponding buffer solution has a pH of 7.0 to 8.2. 23. The method according to claim 22 wherein said serum albumin comprises canine serum albumin. 24. A serum albumin crystal prepared by the method of claim 15, wherein the serum albumin is selected from the group consisting of human serum albumin, baboon serum albumin and canine serum albumin.

Details for Patent 5,585,466

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Grifols Therapeutics Llc	ALBUKED, PLASBUMIN-20, PLASBUMIN-25, PLASBUMIN-5	albumin (human)	For Injection	101138	10/21/1942		2040-01-28
Baxalta Us Inc.	BUMINATE, FLEXBUMIN	albumin (human)	Injection	101452	03/03/1954		2040-01-28
Csl Behring Ag	ALBURX	albumin (human)	Injection	102366	07/23/1976		2040-01-28
Grifols Biologicals Llc	ALBUTEIN	albumin (human)	Injection	102478	08/15/1978		2040-01-28
Instituto Grifols, S.a.	HUMAN ALBUMIN GRIFOLS	albumin (human)	Injection	103352	02/17/1995		2040-01-28